Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2026)

Summit Therapeutics (SMMT) has 8 years of Other Non-Current Liabilities data on file, last reported at $1.8 million in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 1.96% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 million (down 1.96% YoY) and the FY2025 annual result came in at $1.8 million, up 12.39% from the prior year.
• Other Non-Current Liabilities held at $1.8 million in Q2 2026, from $1.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $3.3 million in Q1 2024 to a low of $1.4 million in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 48.52% — and 2024, when it soared 123.5%.
• Tracing SMMT's Other Non-Current Liabilities over 5 years: stood at $1.4 million in 2022, then advanced by 9.31% to $1.6 million in 2023, then rose by 4.35% to $1.6 million in 2024, then rose by 12.39% to $1.8 million in 2025, then retreated by 1.64% to $1.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.8 million (Q2 2026), $1.8 million (Q1 2026), and $1.8 million (Q4 2025), per Business Quant data.